



The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

£1.5 million placing supporting growth of ACCRUFeR®

London, UK, September 15, 2025: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the completion of a placing (the "Placing") to raise gross proceeds of £1.5 million through the issue of 20,000,000 new ordinary shares ("New Ordinary Shares") in the capital of the Company at a price of 7.5 pence per share (the "Issue Price"). This Placing resulted from unsolicited institutional investor demand.

The Issue Price represents a premium of approximately 5% to the 30-day VWAP (Volume Weighted Average Price) of 7.13 pence per existing Ordinary Share to 12 September 2025, being the last trading day prior to the publication of this announcement. The Placing Shares, in aggregate, represent approximately 1.9% of the existing issued ordinary share capital of the Company.

CMC Markets UK Plc, trading as CMC CapX, acted as the Company's sole placing agent in respect of the Placing.

Application has been made to London Stock Exchange plc for the Placing Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place on 19 September 2025. The Placing Shares will be fully paid and will rank *pari passu* in all respects with the existing Ordinary Shares.

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 1,061,690,484 with equal voting rights. No shares are held in treasury.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to (i) the Company's Articles, (ii) the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and/or (iii) the AIM Rules for Companies issued by the London Stock Exchange plc as amended from time to time.

Santosh Shanbhag, CFO at Shield, commented: *"We are pleased with the continued momentum of ACCRUFeR® growth in the US which has now become the #1 branded prescription oral iron in the market today. This placing is in the best interests of the Company by broadening its institutional shareholder base and whilst we remain confident in turning cash flow positive by the end of 2025 it also further strengthens the Company's working capital position allowing the Board and management to focus completely on accelerating sales of ACCRUFeR®"*

For further information please contact:

Shield Therapeutics plc
Anders Lundstrom, CEO
Santosh Shanbhag, CFO
Stephanie Hicks, Investor Relations

www.shieldtherapeutics.com
+44 (0) 191 511 8500
Investorrelations@shieldtx.com

Nominated Adviser and Joint Broker**Peel Hunt LLP**

James Steel

+44 (0)20 7418 8900

Joint Broker**Cavendish Ltd**

Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward

+44 (0)20 7220 0500

Placing Agent**CMC Markets UK Plc**

Thomas Smith

+44 (0)20 3003 8255

About Iron Deficiency and ACCRUFer®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a \$2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFer® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).

ACCRUFer®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFer®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFer®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFer® in the U.S. with an exclusive, multi-year collaboration agreement with Viartis. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFer®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.

ACCRUFer®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFer®/FeRACCRU® are registered trademarks of Shield Therapeutics.

About CMC Markets UK Plc

CMC was established in 1989 and is a FTSE250 listed company. CMC is the second largest domestic stockbroker in Australia, and the group has offices in fourteen countries, with major hubs based in the UK, Germany, Dubai, Singapore, Australia & Canada servicing clients from all around the globe. CMC employs more than fourteen hundred staff and has around one million clients globally.